Company News
SPARC Partner Ocuvex Receives FDA CRL for PDP-716
SPARC's licensing partner Ocuvex Therapeutics received a Complete Response Letter from the US FDA for its PDP-716 New Drug Application.
The FDA's CRL was issued solely due to inspection findings at th
